ARTICLE | Company News
Cardiome, Eddingpharm deal
October 5, 2015 7:00 AM UTC
Cardiome’s Correvio International S.a.r.l. subsidiary granted Eddingpharm exclusive rights to commercialize Aggrastat tirofiban in China. The non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa; CD41/CD61) antagonist is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome and prevent ischemic complications from coronary angioplasty procedures. Cardiome is eligible for milestones and annual commercial commitments. ...